Numaferm, a Dusseldorf University spin-off that specializes in the biotechnical production of peptides, is now receiving funding in the seven-digit range.
Backers included High-Tech Gründerfonds (HTGF), Qiagen co-founders and European business angels Prof. Detlev Riesner and Dr. Jürgen Schumacher, as well as the European Investment Fund.
The company intends to use the funds for the further technological development and an accelerated market entry.
Founded in 2017 as a spin-off of the Biochemistry Institute at the Heinrich-Heine University, Dusseldorf, Numaferm specializes in the biotechnical production of peptides via a fermentative process. The technology, whose basis is the research work of the co-founder Dr. Christian Schwarz, which evolved within the framework of his doctorate at Heinrich-Heine-University in Dusseldorf, holds potential in pharmaceuticals considering the pipeline of more than 500 peptide-based drug candidates.
Through cost reduction, peptides can also be made accessible for entirely new applications, for example special adhesives, feed additives and surface coating.